Deals & Corporate Governance

  • May 01, 2026

    Humana Investor Suit Largely Survives Dismissal Bid

    Health insurer Humana can't shed proposed class action claims it misled investors about the financial impact it would see from pent-up demand for healthcare deferred amid the COVID-19 pandemic, a Delaware federal judge has determined.

  • April 30, 2026

    Acadia Investors Get Final OK For $179M Deal, Atty Fees

    A Tennessee federal judge has given final approval to a $179 million settlement between investors and Acadia Healthcare Co. Inc., ending a class action that alleged the company misled investors about the strength of its U.K. operations.

  • April 27, 2026

    IQVIA Accuses Ex-Execs, Syneos Of Poaching $180M Client

    IQVIA Holdings Inc. is accusing former executives of defecting to a competitor in the clinical research organization industry and initiating a corporate raid that resulted in the loss of one customer worth at least $180 million, according to a lawsuit filed in North Carolina Business Court.

  • April 27, 2026

    4 Firms Build Astorg's $1.1B Microbiology Biz Buy

    Life sciences company Thermo Fisher Scientific Inc. on Monday announced plans to sell its microbiology business to European private equity firm Astorg in an over $1.1 billion deal steered by four law firms.

  • April 27, 2026

    US, Indian Firms Guide $11.75B Sun Pharma-Organon Deal

    Indian pharmaceutical giant Sun Pharmaceutical Industries Ltd. has agreed to acquire New Jersey-based Organon & Co. in an all-cash deal valued at $11.75 billion, with each side of the transaction having representation from one U.S. and one Indian law firm.

  • April 24, 2026

    Natera Tells Justices CareDx Made Up Circ. Split In Petition

    Natera asked the U.S. Supreme Court to reject a petition from rival CareDx asking it to review a Third Circuit decision that erased a $45 million jury verdict stemming from CareDx's false advertising claims, saying Friday the circuit split that CareDx claims exists is "imagined."

  • April 24, 2026

    Taxation With Representation: Gibson Dunn, Paul Weiss

    In this week's Taxation With Representation, Elon Musk's SpaceX strikes a deal with Cursor that could lead to an acquisition of the artificial intelligence startup, building products distributor QXO Inc. buys TopBuild Corp., and Eli Lilly & Co. acquires clinical-stage biotechnology company Kelonia Therapeutics.

  • April 23, 2026

    FTC Cuts Deal To End Anesthesia Group Rollup Case

    The Federal Trade Commission reached an agreement Thursday to settle its case accusing U.S. Anesthesia Partners Inc. of monopolizing the Texas anesthesia services market by purchasing most of the competing anesthesia practices in the state.

  • April 22, 2026

    Full Fed. Circ. Passes On Sarepta's Patent Rehearing Bid

    The full Federal Circuit on Wednesday rejected Sarepta Therapeutics Inc.'s bid for a rehearing after a panel's decision revived a University of Pennsylvania gene therapy patent that is licensed by clinical-stage biotechnology company Regenxbio Inc.

  • April 22, 2026

    Life Policy With $21M Payout Voided As Illegal Life Wager

    A Delaware federal court voided a life insurance policy as an unlawful wager on a now-deceased Florida woman's life, finding that Ameritas Life Insurance Corp. is entitled to retain the policy's $10 million death benefit and $11 million in premium payments.

  • April 22, 2026

    Healthcare REIT Raises $462M In IPO Advised By 4 Firms

    Healthcare-focused real estate investment trust National Healthcare Properties began trading Wednesday after raising $462 million in an initial public offering guided by Paul Weiss, Greenberg Traurig LLP, Sidley Austin LLP and Venable LLP.

  • April 20, 2026

    Providence Health's Sour Investment Cost $70M, Retirees Say

    Retirement plan participants have hit hospital system Providence Health & Services with a proposed class action accusing the Washington-based nonprofit of losing nearly $70 million in assets by sticking with an underperforming mutual fund that lagged behind similar investment options.

  • April 17, 2026

    3 Key Questions On Trump's Pharma Tariffs

    President Donald Trump recently announced 100% tariffs on certain imported pharmaceutical products, with opportunities for drug companies to lower their tariff rates to zero, but questions remain about the requirements for preferential treatment and abilities to administer the regime. Here, Law360 examines three open questions surrounding pharmaceutical tariffs' implementation.

  • April 14, 2026

    Eli Lilly To Purchase Cooley-Led CrossBridge In $300M Deal

    Venture-backed pre-clinical biotechnology firm CrossBridge Bio Inc., advised by Cooley LLP, on Tuesday announced that it has agreed to be bought by pharmaceutical giant Eli Lilly & Co. in a deal worth up to $300 million.

  • April 14, 2026

    Avanos Medical Going Private In $1.3B Deal Led By 3 Firms

    American Industrial Partners has agreed to acquire Avanos Medical Inc. in an all-cash transaction valued at nearly $1.3 billion, a take-private deal steered by three law firms, Avanos announced Tuesday. 

  • April 13, 2026

    Chamber, Other Biz Groups Back Insulin Cos. At High Court

    The U.S. Chamber of Commerce and other business groups urged the U.S. Supreme Court to take up an appeal from Sanofi-Aventis, Eli Lilly, Novo Nordisk and AstraZeneca, arguing the Second Circuit's revival of an antitrust suit risks opening up liability just for trade group membership.

  • April 10, 2026

    Taxation With Representation: Goodwin, CMS, Wilson Sonsini

    In this week's Taxation With Representation, Gilead Sciences Inc. acquires clinical-stage biotechnology company Tubulis GmbH, private equity firm Court Square Capital Partners closes a multibillion-dollar fund and Neurocrine Biosciences Inc. buys rare-disease drugmaker Soleno Therapeutics Inc.

  • April 09, 2026

    Abiomed Can't Escape Blood Pump Patent Case

    A Massachusetts federal judge has refused to let a Johnson & Johnson MedTech subsidiary dodge claims that it infringed a blood pump patent, the latest event in a wider legal battle launched against it by a unit of Swedish medical device company Getinge AB.

  • April 07, 2026

    March's Billion-Dollar Healthcare Deals Signal More To Come

    A smattering of billion-dollar M&A transactions could be the kickoff of an exciting period for dealmaking.

  • April 07, 2026

    The Uncertain Impact Of Medicare Advantage Scrutiny

    The federal government's scrutiny of long-recognized concerns about the Medicare Advantage industry is heating up. Experts are watching to see what long-term changes come of it.

  • April 07, 2026

    ImmunityBio Filmmaker Traded On Insider Tip, SEC Says

    A documentary filmmaker who worked for ImmunityBio Inc. will pay the U.S. Securities and Exchange Commission over $332,000 to end claims she scrambled to sell off her stake in the biotechnology company as it prepared to announce disappointing news about a pending drug application.

  • April 03, 2026

    Law360 Announces The Members Of Its 2026 Editorial Boards

    Law360 is pleased to announce the formation of its 2026 Editorial Advisory Boards.

  • April 03, 2026

    Aetna Escapes COVID Testing Payment Suit In Calif.

    A Nebraska testing laboratory failed to prove that Aetna underpaid more than $53 million for COVID-19 testing services, a California federal judge has ruled, dismissing the lab's federal racketeering and state law claims against the insurer but leaving the door open to an amended suit. 

  • April 02, 2026

    FTC Warns About Ending Tenn. Oversight Of Ballad Health

    Federal Trade Commission staff has warned Tennessee legislators about the potential harm to patients if they pass a proposal to end the state's oversight of Ballad Health while the hospital system still has a monopoly.

  • April 02, 2026

    Alexion Beats Trade Secret Claims In Amyndas Suit

    Amyndas Pharmaceuticals failed to specifically identify the trade secrets it claimed pharmaceutical company Alexion learned of during early partnership talks and improperly used to launch a business collaboration with another competitor, a Massachusetts federal judge has found.

Expert Analysis

  • Calif. Case Raises Questions For Medical Practice Investors

    Author Photo

    The California attorney general's amicus brief in Art Center v. WCE and the California Medical Association's response highlight how the California appeals court's ruling could significantly affect the structure and enforceability of succession arrangements in medical practice ownership, say attorneys at Ropes & Gray.

  • How CMS Fraud Priorities Complicate Provider Acquisitions

    Author Photo

    As the Centers for Medicare & Medicaid Services steps up usage of its affiliates authority and post-transaction audits, parties contemplating the acquisition or sale of home health and hospice providers should take steps to avoid the potential suspension of Medicare billing privileges, say attorneys at Alston & Bird.

  • The Challenge Of Stabilizing Rural Hospitals On The Brink

    Author Photo

    The outlook for rural hospitals has grown more concerning, as recent policy and regulatory developments are decreasing hospital revenues and increasing the cost of uncompensated care, which may result in additional hospital closures, service reductions, or mergers and acquisitions, say Omur Celmanbet, Kristy Piccinini and Sabiha Quddus at FTI Consulting.

  • Bid Protest Spotlight: Evidence, Tailored Talks, Materiality

    Author Photo

    In this month's bid protest roundup, Brian Doll at MoFo delves into three recent decisions from the Government Accountability Office about the evidentiary standards necessary to sustain a protest, discussions tailored to individual proposals, and misrepresentation claims involving factors irrelevant to the agency's decision.

  • Senior Housing Demands A Distinct Dealmaking Playbook

    Author Photo

    An aging population and evolving state regulations underscore a critical reality that senior housing assets can undergo operational or compliance shifts during dealmaking, highlighting the need for unique contractual safeguards like expanded disclosures, anchored notice obligations, and targeted closing conditions and remedies, say attorneys at Goodwin.

  • OhioHealth Suit Signals Higher Antitrust Heat On Hospitals

    Author Photo

    The recent antitrust lawsuit against OhioHealth by the U.S. Justice Department and Ohio attorney general shows that federal and state enforcers are closely examining the competition issues in the healthcare sector, including restrictive contracts and antisteering practices, say attorneys at Freshfields.

  • What Changed For Healthcare Transaction Law In 2025

    Author Photo

    Though much of the legislation introduced last year to expand state scrutiny of healthcare transactions did not pass, investors should pay close attention to the overarching trends, which are likely to continue in this year's legislative sessions, say attorneys at Ropes & Gray.

  • Key Trends In Healthcare Antitrust In 2025

    Author Photo

    The healthcare industry braced for significant antitrust enforcement shifts last year driven by a change in administration, and understanding the implications of these trends is critical for healthcare organizations' risk management and strategic decision-making in the year ahead, say attorneys at Michael Best.

  • The 5 Most Important Bid Protest Decisions Of 2025

    Author Photo

    In a shifting bid protest landscape, five decisions in 2025 from the Federal Circuit, the U.S. Court of Federal Claims and the U.S. Government Accountability Office that addressed bedrock questions about jurisdictional reach and the breadth of agency discretion are likely to have a lasting impact, say attorneys at Bradley Arant.

  • Top 5 Antitrust Issues For In-House Counsel To Watch In 2026

    Author Photo

    With Trump administration enforcement policy having largely taken shape last year, antitrust issues that in-house counsel should have on the radar range from scrutiny of technology-assisted pricing to the return of merger remedies, say attorneys at Squire Patton.

  • Nonprofits Face Uncertainty Over Political Activity Rules

    Author Photo

    Two federal court decisions suggesting that the Internal Revenue Service's rules for 501(c)(4) organizations' political activity may be too vague to survive constitutional scrutiny leave nonprofit organizations caught between constitutional limits on government regulation of speech and tax limits on their exempt status, say attorneys at BakerHostetler.

  • Key Takeaways From Armed Services Board's FY 2025 Report

    Author Photo

    The Armed Services Board of Contract Appeals’ annual report reveals an increase in new cases filed, but a decrease in cases resolved, and fewer parties choosing alternative dispute resolution, despite the likely reduction in time and expenses incurred during a prolonged appeal process, say attorneys at Miller & Chevalier.

  • IP Ownership Risk Grows In Booming Cancer Drug Market

    Author Photo

    The ownership of intellectual property has become strategically decisive in deals involving valuable cancer therapeutics known as ADCs, as highlighted by the recent Takeda-Innovent deal, with the commercial value of a license resting on the integrity and defensibility of the underlying technology, say attorneys at Loeb & Loeb.